Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER⁺ Breast Cancer.

ABSTRACT:

Purpose

Recent preclinical data suggest that cyclin-dependent kinase 4/6 (CDK4/6) inhibition may be harnessed to sensitize estrogen receptor-positive (ER⁺) breast cancer to radiotherapy. However, these findings were obtained in human ER⁺ breast cancer cell lines exposed to subclinical doses of CDK4/6 inhibitors with limited attention to treatment schedule. We investigated the activity of radiotherapy combined with the prototypic CDK4/6 inhibitor palbociclib placing emphasis on therapeutic schedule.

Experimental design

We combined radiotherapy and palbociclib in various doses and therapeutic schedules in human and mouse models of ER⁺ and ER-negative (ER^-) breast cancer, including an immunocompetent mouse model that recapitulates key

SUBMITTER: Petroni G 

PROVIDER: S-EPMC8327758 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature